IVD Big Four, Roche, Abbott, Danaher, Siemens who are the most cattle

Medical Network April 28 hearing as of April 26, with the Roche 2018 Q1 financial report released, IVD Top4 in the 2018 Q1 financial report all announced.

The ranking of IVD's Big Four, which was previously without Siemens Medical's diagnosis business, has always been a mystery. Then, with the independent release of Siemens Medical Financial Report, the answer is about to unveil!

In Q18, Q1, there was a major change in the diagnostics business rankings:

Roche first, Abbott second, Danaher third, Siemens medical fourth.

Roche: Still ahead in the diagnostics field, Q1's top-ranked Abbott revenue is about $1 billion.

Abbott: Q1 brought 58.7% high growth through acquisition, Abbott returned to IVD second.

Danaher: The diagnostic business continued to grow at a high rate, +14.5% year-on-year. If the impact of exchange rates and mergers and acquisitions were deducted, the growth rate of the Big Four was fast. enterprise The gap between Q1 and Abbott is only $300 million.

Siemens Healthcare: Due to the influence of the U.S. market, Siemens' medical diagnostics business fell (-1.1%) to fourth place. It is similar to Danaher's diagnostic business ranked third, which is approximately US$400 million.

The high funds raised by Siemens Medical listing also made it possible for the IVD giants to finish qualifying in 2018.

2017 (million)	Roche (CHF)	Abbott (US dollar)	Danaher (US dollar)	Siemens Healthineers (EUR)
Total revenue	13583	7390	4695.4	3198
Total revenue growth rate	6%	6.9%; 16.7%	11.6%	2.3%
Diagnostic services Change in ranking	→	↑	↓	↓2
Diagnostic services income	2911	1837	1519.7	929
Diagnostic services growth rate	5%	5.5%; 58.7%	14.5%	-1.1%
Diagnostic services Accounting	21%	24.9%	32.4%	29%

▲IVD Top4 Enterprise 2018 Q1 Data Overview

Note: 1 Abbott growth rate column, 6.9% as comparable growth rate, excluding the impact of foreign exchange and mergers and acquisitions; 16.7% year-on-year growth rate; diagnostic business growth rate data ibid.

2 According to the real-time exchange rate, 1 Swiss franc = 1.0168 US dollars, Roche's total revenue was approximately 13,811 million US dollars, and the diagnostic business revenue was approximately 2,960 million US dollars.

31 Euro = 1.2177 US dollars, Siemens Medical's total revenue of about 3894 million US dollars, diagnostic business revenue of about 1131 million US dollars.

With its organic combination of 'Pharmaceuticals + Diagnostics', Roche has a leading position in the pharmaceutical and IVD industries. Diagnostic is the long-term market leader.

Roche's Q1 revenue in 2008 was 13.6 billion Swiss francs, +6% year-on-year.

With its organic combination of 'Pharmaceuticals + Diagnostics', Roche has a leading position in the pharmaceutical and IVD industries. Diagnostic is the long-term market leader.

Roche's Q1 revenue in 2008 was 13.6 billion Swiss francs, +6% year-on-year.

▲ Roche 2018 Q1 financial data

The diagnostics division contributed 2.9 billion Swiss francs of revenue, +5% year-on-year, driven by the growth of all businesses; it accounted for 21% of total revenue, a slight decrease from the 23% share in 2017.

▲ Roche Diagnostics Four Businesses 2018 Q1 Data

Central Laboratory and POC Diagnostics Division: The main contributor to diagnostics business revenue, accounting for up to 59%. Revenues 1.716 billion Swiss francs, +4% year-on-year. Among them, immune diagnosis +5% year-on-year, Clinical Chemistry +3 %, POC products showed a downward trend (-2%).

Diabetes Management Business: Revenue of 477 million Swiss francs, accounting for 16% of diagnostic business revenues. In 2017, diabetes management business was the worst performing business in Roche Diagnostics (-4%), and the business performed positively in Q1 in 2018. The drop was +5%. Mainly driven by the 24% increase in U.S. blood glucose monitoring business volume.

Molecular diagnostics business: Revenue 468 million Swiss francs, accounting for 16%, +6% year-on-year.

The strong flu boosted sales of the cobas® Liat® system, up 262% year-on-year;

Released a cobas® plasma separation card for the detection of HIV virus in resource-limited settings, contributing to a 20% increase;

Human papillomavirus diagnosis increased by 5%;

Virology field +5%.

Organizational diagnostics business: Revenue of 249 million Swiss francs, accounting for 9%, an increase of 7%.

Roche Diagnostics 2018 Q1 regional revenue data

Roche diagnosis is mainly driven by the Asia-Pacific region and North America in the region.

EMEA (Europe, Middle East, Africa): The largest market for Roche Diagnostics, accounting for 42% of diagnostic revenue, +2% year-on-year;

North America: The second largest market, accounting for 26% of diagnostic revenues; Roche's diagnosis in the North American market basically stabilized in 2017, while in Q18 of 2018, the North American market grew strongly (+7%);

Asia Pacific: Accounting for 23% of diagnostic revenues, Roche’s main source of growth, up +10%;

Latin America: accounting for 6% of diagnostic revenue, +1% year-on-year;

Japan: Only accounted for 3% of diagnostic revenue, but it fell significantly (-8%).

Roche Diagnostics has continued to maintain a stable growth (5%-6%) as the Big Mac in the IVD industry, but Abbott, Danaher, and Roche overtaking through cornering mergers and acquisitions also need to constantly look for new growth points.

At the beginning of 2018, Roche's intelligent IT products were upgraded to the first place in China Medical University. hospital Inspection Section. Launched the iPad mobile product including iBoard process monitoring system and intelligent remote control system, and changed the remote control from the PC to the medical terminal.

At the end of 2017, Abbott Global CEO Miles D. White once said: 'We will enter the 2018 with very good momentum.'

As Bai Qianli predicted, Abbott's start was very strong in 2018.

Abbott's revenue in the 2018 Q1 business was US$7.39 billion, a year-on-year increase of 16.7%. After deducting the impact of the acquisition and exchange rate, it increased by 6.9%, which is still higher than the 4.9% growth in 2017.

▲ Abbott 2018 Q1 overall revenue data

▲ Abbott 2018 Q1 Revenue from Each Business

Abbott's revenue of $1.837 billion was diagnosed, and the synergies brought by the acquisition of Alere were significant. The diagnostic business grew at a staggering rate of 58.7% (compared with an increase of 5.5% after the acquisition and exchange rate impact).

The diagnostic business accounted for nearly 24% of the total revenue. Compared with 20% of the whole year of 2017, it achieved a significant increase. The diagnostic business also became Abbott’s second largest business from the previous third largest business.

Due to the impact of the acquisition of Alere's new business segment, the rapid diagnostic business, Abbott’s original three major segments (traditional diagnostics, molecular diagnostics, and bedside diagnostics) account for the proportion of diagnostic business revenue. Sliding.

▲Abbott Diagnostics 2018 Q1 Revenue Data

Traditional diagnostics: Revenue of $1,019 million, +11.9% YoY. 5.6% growth was due to the favorable impact of foreign exchange. Revenue from business accounting for 55% of diagnostics business, which is a significant increase compared to 2017 (72%). Sliding.

Molecular diagnostics: Revenue was only $180 million, +5.0% year-on-year. The lowest share in diagnostics was only 6%.

Molecular Diagnostics Core Area Infectious disease Strong test growth.

After a 12.8% decline in 2017, the molecular diagnosis continued to decline in the US market, and the Q1 fell again to a new high (-13.8%) in 2018. However, the international market was strong, with a high growth rate of 17.5%. The increase in performance is an upward trend.

However, the promotion of molecular diagnostics in the US market is a problem that Abbott must face in diagnosis.

Bedside diagnosis (Abbott’s traditional POC business): revenue of US$141 million, +4.8% year-on-year, accounting for 8% of diagnostic business. Compared to the US market with only 0.6% growth, up to 23% in the international market grew very much Bright eyes, mainly driven by the i-STAT® handheld system.

Rapid diagnosis (Alere's POC business): Revenue of $559 million, which contributed 30% of diagnostic business revenue. The revenue of this business is mainly derived from the detection of infectious diseases (including flu).

In view of the fact that the product lines for bedside diagnosis and rapid diagnosis actually overlap, the two businesses are likely to merge in the future. The POC business accounts for about 40% of the total and becomes the second largest business for Abbott Diagnostics.

US market: Revenue was US$700 million, +89.2% year-on-year, but only 1.8% after deduction of acquisitions and foreign exchange effects. In addition to rapid diagnosis business, the growth rate of each sub-business in the US market was lower than the international market.

International Markets: Revenue of US$1.137 billion, +44.3% year-on-year, and a comparable increase of +7.3%. It contributed 62% of the revenue of the diagnostic business.

In 2018, it will be the year that Abbott’s acquisition of Alere witnessed the rapid growth of diagnostic services.

Abbott also continues to advance the process of new products in the Chinese market. On March 22nd, Abbott’s next-generation diagnostic product, Alinity ci, was officially launched in China.

In 2018 Q1, Danaher continued to maintain its high growth, with revenue of $4.695 billion, +11.6% from the same period of last year. Life sciences, diagnostics, and environmental applications all achieved over 12% growth.

▲ Danaher 2018 Q1 data

Danaher's diagnostic business had a weak advantage at the end of 2017, overtaking Abbott and occupying the second throne.

In Q1, 2018, after Abbott’s acquisition of Alere’s diagnostic business grew rapidly, Danaher’s diagnostic revenue was approximately $300 million behind Abbott’s diagnosis, ranking third.

Danaher's diagnostic business revenue was US$1.52 billion in Q1, up +14.5% year-on-year. It was the highest growth business in Danaher's four businesses and accounted for 32.4% of total revenue. The growth was driven mainly by Cepheid, and the net profit of the business was yoy. +16.3%.

▲ Danaher 2018 Q1 Diagnostics Business Revenue

▲ Danaher 2018 Q1 Regional Revenue

North America: Danaher’s largest market for diagnostic services, which contributed US$607 million in revenue, accounting for 40% of diagnostics business;

Western Europe: Revenue of 310 million U.S. dollars, accounting for 20%;

Other development markets: Revenue of US$92 million, accounting for 6%;

High-growth markets (Eastern Europe, Middle East, Africa, Latin America, Asia, Japan excluded): Revenue of US$510 million, accounting for 34%.

At the beginning of 2018, Danaher took the initiative in the acquisition of diagnostics:

On March 9th, Danaher announced the acquisition of Integrated DNA Technologies (IDT) to provide high-value consumables for genomic applications such as molecular biology, qPCR, next-generation sequencing, synthetic biology, gene editing, and molecular diagnostics.

Danaher's diagnosis business is full of imagination because of its continuous high growth.

Siemens Healthcare released its financial report for the first time after independence from Siemens.

The total revenue of Siemens Medical in Q1 in 2018 was 3.22 billion euros, excluding the impact of exchange rate, and the revenue was +2.3% compared to the same period last year. The growth was mainly driven by the imaging business and advanced treatment business.

▲ Siemens Medical 2018 Q1 revenue data

▲Siemens Medical Diagnostics Business 2018 Q1 Revenue Data

In Q18, Q1, Siemens Medical Diagnostics reported revenue of 929 million euros, which was affected by the commercialization of AtellicaTM Solution, the next-generation immune and biochemical solution in the United States, and the impact of foreign exchange. The diagnostic business fell by 1.1%.

Siemens Medical Revenue achieved high growth in EMEA (Europe, Middle East and Africa, Europe, Middle East and Africa) and China.

In terms of diagnostic business, revenue in the United States decreased, and income in other regions remained stable.

On March 16th, Siemens Medical Frankfurt Exchange successfully listed, IPO raised 4.2 billion euros (5.2 billion US dollars). Siemens Medical said before the listing, part of the funds raised will be used for mergers and acquisitions, and the diagnostic business is the focus of its development, hope Raise revenue to 4%-6%.

Therefore, Siemens Healthcare is likely to boost its diagnostic business through mergers and acquisitions in the next two years.

It can be seen that apart from the position of Roche’s boss, Abbott, No. 3 Danaher, No. 4 Siemens Medical, the diagnostic business revenue gap is only 3-4 billion US dollars. The smell of smoke on the battlefield is very strong. After Abbott and Danaher get high growth through mergers and acquisitions, will Siemens with large amounts of money on hand, will it go through mergers and acquisitions?

Remarks: The above data comes from quarterly reports and annual reports of companies.